QSAR and 3D QSAR in drug design .1. methodology

被引:312
|
作者
Kubinyi, H
机构
[1] Drug Design, ZHV/W-A30, BASF AG
关键词
D O I
10.1016/S1359-6446(97)01079-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Classical QSAR methods describe structure-activity relationships in terms of physicochemical parameters and steric properties (Hansch analysis, extrathermodynamic approach), or certain structural features (Free Wilson analysis). 3D QSAR methods, especially comparative molecular field analysis, consider the three-dimensional structures and the binding modes of protein ligands. Quantitative similarity-activity relationships derive correlations between the similarities of individual compounds and their biological activities. Theory and methodology of these approaches are described here, together with the proper use of regression and partial least squares analyses for deriving quantitative structure-activity relationships. Part 2, to be published in the December issue, will address applications and problems.
引用
收藏
页码:457 / 467
页数:11
相关论文
共 50 条
  • [31] Finding optimum field models for 3D QSAR
    Kellogg, GE
    MEDICINAL CHEMISTRY RESEARCH, 1997, 7 (6-7) : 417 - 427
  • [32] 3D connectivity indices in QSPR/QSAR studies
    Estrada, E
    Molina, E
    JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2001, 41 (03): : 791 - 797
  • [33] Pharmacophore and 3D QSAR Study of TGFβ Inhibitors
    Vazhapully, Mohamed Asraf
    Vinod, D.
    Hukuman, N. H. Zeinul
    LETTERS IN DRUG DESIGN & DISCOVERY, 2014, 11 (03) : 316 - 330
  • [34] Automatic generation of alignments for 3D QSAR analyses
    Jewell, NE
    Turner, DB
    Willett, P
    Sexton, GJ
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2001, 20 (02): : 111 - 121
  • [35] 3D QSAR study of the toxicity of trichothecene mycotoxins
    Steinmetz, Wayne E.
    Rodarte, Cezar B.
    Lin, Alvin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (11) : 4485 - 4489
  • [36] Dynamic 3D QSAR techniques: applications in toxicology
    Mekenyan, O
    Nikolova, N
    Schmieder, P
    JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM, 2003, 622 (1-2): : 147 - 165
  • [37] 3D QSAR: Current state, scope, and limitations
    Martin, YC
    PERSPECTIVES IN DRUG DISCOVERY AND DESIGN, 1998, 12 : 3 - 23
  • [38] QSAR of 1,4-benzoxazin-3-one antimicrobials and their drug design perspectives
    de Bruijn, Wouter J. C.
    Hageman, Jos A.
    Araya-Cloutier, Carla
    Gruppen, Harry
    Vincken, Jean-Paul
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (23-24) : 6105 - 6114
  • [39] Modeling robust QSAR. 1. Coding molecules in 3D-QSAR - from a point to surface sectors and molecular volumes
    Gieleciak, R
    Magdziarz, T
    Bak, A
    Polanski, J
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2005, 45 (05) : 1447 - 1455
  • [40] 3D-QSAR Approaches in Drug Design: Perspectives to Generate Reliable CoMFA Models
    Melo-Filho, Cleber Camilo
    Braga, Rodolpho Campos
    Andrade, Carolina Horta
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2014, 10 (02) : 148 - 159